Complete Genomics (GNOM) & Evolent Health (EVH) Financial Comparison

Complete Genomics (NASDAQ: GNOM) and Evolent Health (NYSE:EVH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations for Complete Genomics and Evolent Health, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Complete Genomics 0 0 0 0 N/A
Evolent Health 0 0 14 0 3.00

Evolent Health has a consensus price target of $28.00, indicating a potential upside of 108.96%. Given Evolent Health’s higher probable upside, analysts clearly believe Evolent Health is more favorable than Complete Genomics.

Earnings & Valuation

This table compares Complete Genomics and Evolent Health’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Complete Genomics N/A N/A N/A ($2.35) -1.34
Evolent Health $254.19 million 4.08 -$159.74 million ($1.14) -11.75

Complete Genomics has higher earnings, but lower revenue than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Complete Genomics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

95.4% of Evolent Health shares are owned by institutional investors. 8.8% of Evolent Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Complete Genomics and Evolent Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Complete Genomics N/A N/A N/A
Evolent Health -15.86% -5.05% -3.96%

Summary

Evolent Health beats Complete Genomics on 6 of the 10 factors compared between the two stocks.

About Complete Genomics

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

About Evolent Health

Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company’s services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company’s technology platform that aggregates and analyzes data, manages care workflows and engages patients.

Receive News & Ratings for Complete Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Complete Genomics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply